Systemic availability of itraconazole in lung transplantation

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 9, 1996, Pages 2217-2220

  Patterson, Thomas F ^a   Peters, Jay ^a   Levine, Stephanie M ^a   Anzueto, Antonio ^a   Bryan, Charles L ^a   Sako, Edward Y ^a   Miller, O Lawayne ^a   Calhoon, John H ^a   Rinaldi, Michael G ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CYCLODEXTRIN; CYCLOSPORIN; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; RANITIDINE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MIXTURE; HUMAN; IMMUNE DEFICIENCY; INFECTION CONTROL; LUNG TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL;

EID: 0029844276     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.9.2217     Document Type: Article

References (13)

1. Barone, J. A., J. G. Koh, R. H. Bierman, J. L. Colaizzi, K. A. Swanson, M. C. Gaffar, B. L. Moskovitz, W. Mechlinski, and V. Van De Velde. 1993. Food interaction and steady-stale pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob. Agents Chemother. 37:778-784.
2. Bodet, C. A., III, J. H. Jorgensen, and D. J. Drutz. 1985. Simplified bioassay method for measurement of flucytosine or ketoconazole. J. Clin. Microbiol. 22:157-160.
3. Denning, D. W., J. Y. Lee, J. S. Hosteller, P. Pappas, C. A. Kauffman, D. H. Dewsnup, J. N. Galgiani, J. R. Graybill, A. M. Sugar, A. Catanzaro, H. Gallis, J. R. Perfect, B. Dockery, W. E. Dismukes, and D. A. Stevens. 1994. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 97:135-144.
4. Denning, D. W., and D. A. Stevens. 1990. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12:1147-1201.
5. Graybill, J. R. 1989. New antifungal agents. Eur. J. Clin. Microbiol. Infect. Dis. 5:402-412.
6. 2 blockers, abstr. A36, p. 39. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Hardin, T. C., J. R. Graybill, R. Fetchick, R. Woestenborghs, M. G. Rinaldi, and J. G. Kuhn. 1988. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 32:1310-1313.
8. Hostetler, J. S., L. H. Hanson, and D. A. Stevens. 1992. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob. Agents Chemother. 36:477-480.
9. Hostetler, J. S., J. Heykants, K. V. Clemons, R. Woestenborghs, L. H. Hanson, and D. A. Stevens. 1993. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob. Agents Chemother. 37:2224-2227.
10. Negroni, R., and A. I. Arechavala. 1993. Itraconazole: pharmacokinetics and indications. Arch. Med. Res. 24:387-393.
11. Patterson, T. F., A. W. Fothergill, and M. G. Rinaldi. 1993. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother. 37:2307-2310.
12. 2-blocker therapy, abstr. A38, p. 39. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Van Peer, A., R. Woestenborghs, J. Heykants, R. Gasparini, and G. Gauwenbergh. 1989. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur. J. Clin. Pharmacol. 36:423-426.